CRL
Charles River Laboratories International, Inc.
September 24, 2026 · market open
- Rarity
- 1.64
- Peak move
- +7.64%
- Float cap
- $13.5B
Charles River Laboratories International, Inc. is a non-clinical global drug development partner. It provides discovery and safety assessment services, both Good Laboratory Practice and non-GLP, as well as products and services for manufacturing. The company serves pharmaceutical and biotechnology clients, supporting target identification through non-clinical development.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
4 events · 1 from SEC or newswire · 0 timed with the moveguidance_changeCharles River Laboratories held its Investor Day on September 24, 2026, unveiling the 'Pathway to Purpose' strategy with 2030 targets of 5%-7% organic revenue CAGR, ~24% non-GAAP operating margin, low-double-digit EPS CAGR, over $300 million in Create the Future savings, and ~$450 million bioanalysis revenue, while reaffirming 2026 guidance and expecting revenue growth of 0%-1% and non-GAAP EPS of $11.15-$11.45 at the upper ends of their ranges.
SEC8-K 0001100682-26-000142Websec.govWebinvestingnews.comWebbarchart.comWebbarchart.comWebsec.govWebsec.govWebapp.quotemedia.comWebinvestingnews.comSEC8-K 0001100682-26-000142analyst_ratingEvercore ISI said Charles River's 5%-7% organic revenue growth target for 2027-2030 is above expectations and 'highly achievable under normal market conditions,' while calling the ~24% 2030 margin target somewhat surprising given the $300 million cost-savings plan.
peer_disclosureEli Lilly's AI drug discovery platform Lilly TuneLab added Genscript Biotech, Twist Bioscience and Ginkgo Bioworks as wet-lab service suppliers on September 16 for protein expression, antibody characterization and small-molecule ADME work.
demand_signalAnthropic built a wet lab in the San Francisco Bay Area where its Claude models direct physical biological experiments and lab robotics, with life sciences among its largest investment areas.